GH
Guardant Health Inc
$161.41+0.23%
Setup
No setup
Buy Zone
$164.7-$172.94
Sector
Diagnostics & Research
Industry
Diagnostics & Research
58
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
GH chart
Loading chart…
ADX
Strong47.9Long Term
Up ↑Intermediate Term
Up ↑Short Term
Up ↑Overall Quality58
RS Rating
95
relative strength
Fundamentals
41
Weak fund-Q
Volume Demand
82
-5% vs avg
Technical Setup
63
5/8 checks
Industry/Theme
91
Diagnostics & Research
Trade Plan
Avoid
Entry
$164.7
Entry Zone
$164.7-$172.94
Stop / Risk
$151.52
RS Rating
95
Volume confirmed
Yes
Targets
$197.64 / $205.88
Breakout · IBD Setup
6 ✓ 2 ✗
Entry $164.7–$172.94Stop $151.52Target $197.64 / $205.88
Market regimeUptrend
Quality58
RS Rating95
Above 50-MA+1.19%
Above 200-MA+37.51%
VolumeConfirmed
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
58
MarketUptrend
SetupNo setup
ConfidenceExperimental · not backtested
Fund-Q41 · Weak
StatusAvoid
Stock Data
52-Week Range53 – 177
Price % Chg YTD58.03%
Price % Chg 4wk2.43%
50-Day Avg Vol2.5 Mil
P/E Ratio—
Market Cap$22B
SectorHealthcare
IndustryDiagnostics & Research
Company Fundamentals
EPS % Chg (Qtr)-12.34%
Sales % Chg (Qtr)44.33%
EPS Growth 5y-4.99%
Sales Growth 5y27.92%
Annual ROE—
Gross Margin65.01%
Operating Margin-39.7%
Net Margin-38.33%
Debt / Equity—
Setup levels
Current price
$161.41
Pivot
$164.7
Distance to buy
-8.6%
52-week range
53.4-176.58
Trigger evidence
No active trigger evidence available.
Financial health checks
1/3
Net margin above 10%
Net margin -38.33%
EPS growing quarter on quarter
EPS q/q -12.34%
Sales growing quarter on quarter
Sales q/q 44.33%
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE—
Net margin-38.33%
vs sector -55.3%
Gross margin65.01%
vs sector -1.6%
EPS growth q/q-12.34%
vs sector -20.4%
Sales growth q/q44.33%
vs sector +25.8%
Debt / equity—
lower is better
Business quality
41
GradeWeak
EPS rating22
P/E—
Market cap$22B
IndustryDiagnostics & Research
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Fail
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-09-06
Trigger date
—
Days on list
1
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.